# Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer

> **NCT01303705** · PHASE1 · COMPLETED · sponsor: **Providence Health & Services** · enrollment: 13 (actual)

## Conditions studied

- Metastatic Prostate Cancer
- Cancer of the Prostate
- Prostate Cancer

## Interventions

- **DRUG:** Anti-OX40
- **RADIATION:** Radiation
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT01303705
- **Lead sponsor:** Providence Health & Services
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-14
- **Primary completion:** 2016-07-05
- **Final completion:** 2016-07-05
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2018-08-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01303705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01303705, "Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01303705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*